Esperion Therapeutics, Inc. 8-K
Research Summary
AI-generated summary
Esperion Therapeutics Reports Q4 and FY 2025 Financial Results
What Happened
Esperion Therapeutics, Inc. announced its financial results for the three months and year ended December 31, 2025 via a press release dated March 10, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release and disclosed the filing was signed by President and CEO Sheldon L. Koenig.
Key Details
- Filing date: March 10, 2026 (Form 8-K).
- Reporting period: three months and year ended December 31, 2025.
- Press release furnished as Exhibit 99.1 to the 8-K (Press Release dated March 10, 2026).
- Form signed by Sheldon L. Koenig, President and Chief Executive Officer.
Why It Matters
This 8-K signals Esperion has publicly released its latest quarterly and full-year financial results — the primary source for revenue, earnings, cash position, and any commentary on outlook or business trends. Retail investors should review the Exhibit 99.1 press release for the actual financial figures and management commentary, since the 8-K itself only furnishes the release rather than restating detailed results.